β-adrenergic receptor stimulation transactivates protease-activated receptor 1 via matrix metalloproteinase 13 in cardiac cells

F Jaffré, AE Friedman, Z Hu, N Mackman, BC Blaxall - Circulation, 2012 - Am Heart Assoc
F Jaffré, AE Friedman, Z Hu, N Mackman, BC Blaxall
Circulation, 2012Am Heart Assoc
Background—Chronic β-adrenergic receptor (β-AR) overstimulation, a hallmark of heart
failure, is associated with increased cardiac expression of matrix metalloproteinases
(MMPs). MMP-1 has been shown to cleave and activate the protease-activated receptor 1
(PAR1) in noncardiac cells. In the present study, we hypothesized that β-AR stimulation
would result in MMP-dependent PAR1 transactivation in cardiac cells. Methods and Results—
β-AR stimulation of neonatal rat ventricular myocytes (NRVMs) or cardiac fibroblasts with …
Background
Chronic β-adrenergic receptor (β-AR) overstimulation, a hallmark of heart failure, is associated with increased cardiac expression of matrix metalloproteinases (MMPs). MMP-1 has been shown to cleave and activate the protease-activated receptor 1 (PAR1) in noncardiac cells. In the present study, we hypothesized that β-AR stimulation would result in MMP-dependent PAR1 transactivation in cardiac cells.
Methods and Results
β-AR stimulation of neonatal rat ventricular myocytes (NRVMs) or cardiac fibroblasts with isoproterenol transduced with an alkaline phosphatase–tagged PAR1 elicited a significant increase in alkaline phosphatase–PAR1 cleavage. This isoproterenol-dependent cleavage was significantly reduced by the broad-spectrum MMP inhibitor GM6001. Importantly, specific MMP-13 inhibitors also decreased alkaline phosphatase–PAR1 cleavage in isoproterenol-stimulated NRVMs, as well as in NRVMs stimulated with conditioned medium from isoproterenol-stimulated cardiac fibroblasts. Moreover, we found that recombinant MMP-13 stimulation cleaved alkaline phosphatase–PAR1 in NRVMs at DPRS4243FLLRN. This also led to the activation of the ERK1/2 pathway through Gαq in NRVMs and via the Gαq/ErbB receptor pathways in cardiac fibroblasts. MMP-13 elicited similar levels of ERK1/2 activation but lower levels of generation of inositol phosphates in comparison to thrombin. Finally, we demonstrated that either PAR1 genetic ablation or pharmacological inhibition of MMP-13 prevented isoproterenol-dependent cardiac dysfunction in mice.
Conclusions
In this study, we demonstrate that β-AR stimulation leads to MMP-13 transactivation of PAR1 in both cardiac fibroblasts and cardiomyocytes and that this likely contributes to pathological activation of Gαq and ErbB receptor–dependent pathways in the heart. We propose that this mechanism may underlie the development of β-AR overstimulation–dependent cardiac dysfunction.
Am Heart Assoc